161 related articles for article (PubMed ID: 38211393)
1. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract][Full Text] [Related]
2. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
3. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
[TBL] [Abstract][Full Text] [Related]
4. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Harding JJ; Piha-Paul SA; Shah RH; Murphy JJ; Cleary JM; Shapiro GI; Quinn DI; Braña I; Moreno V; Borad M; Loi S; Spanggaard I; Park H; Ford JM; Arnedos M; Stemmer SM; de la Fouchardiere C; Fountzilas C; Zhang J; DiPrimeo D; Savin C; Duygu Selcuklu S; Berger MF; Eli LD; Meric-Bernstam F; Jhaveri K; Solit DB; Abou-Alfa GK
Nat Commun; 2023 Feb; 14(1):630. PubMed ID: 36746967
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.
Yuan Y; Lee JS; Yost SE; Stiller T; Blanchard MS; Padam S; Katheria V; Kim H; Sun C; Tang A; Martinez N; Patel ND; Sedrak MS; Waisman J; Li D; Sanani S; Presant CA; Mortimer J
J Geriatr Oncol; 2021 Jun; 12(5):752-758. PubMed ID: 33663941
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; Ow S; Kim SB; Lin J; Chung HC; Ngan R; Kok VC; Rau KM; Sangai T; Ng TY; Tseng LM; Bryce R; Bebchuk J; Chen MC; Hou MF
Breast Cancer Res Treat; 2021 Oct; 189(3):665-676. PubMed ID: 34553296
[TBL] [Abstract][Full Text] [Related]
7. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Chan A; Ruiz-Borrego M; Marx G; Chien AJ; Rugo HS; Brufsky A; Thirlwell M; Trudeau M; Bose R; García-Sáenz JA; Egle D; Pistilli B; Wassermann J; Cheong KA; Schnappauf B; Semsek D; Singer CF; Foruzan N; DiPrimeo D; McCulloch L; Hurvitz SA; Barcenas CH
Breast; 2023 Feb; 67():94-101. PubMed ID: 36702070
[TBL] [Abstract][Full Text] [Related]
8. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
[TBL] [Abstract][Full Text] [Related]
9. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
10. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
[TBL] [Abstract][Full Text] [Related]
11. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
[TBL] [Abstract][Full Text] [Related]
12. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
13. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
Ben-Baruch NE; Bose R; Kavuri SM; Ma CX; Ellis MJ
J Natl Compr Canc Netw; 2015 Sep; 13(9):1061-4. PubMed ID: 26358790
[TBL] [Abstract][Full Text] [Related]
14. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.
Chow LW; Xu B; Gupta S; Freyman A; Zhao Y; Abbas R; Vo Van ML; Bondarenko I
Br J Cancer; 2013 May; 108(10):1985-93. PubMed ID: 23632474
[TBL] [Abstract][Full Text] [Related]
15. Neratinib Efficacy and Circulating Tumor DNA Detection of
Ma CX; Bose R; Gao F; Freedman RA; Telli ML; Kimmick G; Winer E; Naughton M; Goetz MP; Russell C; Tripathy D; Cobleigh M; Forero A; Pluard TJ; Anders C; Niravath PA; Thomas S; Anderson J; Bumb C; Banks KC; Lanman RB; Bryce R; Lalani AS; Pfeifer J; Hayes DF; Pegram M; Blackwell K; Bedard PL; Al-Kateb H; Ellis MJC
Clin Cancer Res; 2017 Oct; 23(19):5687-5695. PubMed ID: 28679771
[No Abstract] [Full Text] [Related]
16. HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM; Piha-Paul SA; Won H; Rodon J; Saura C; Shapiro GI; Juric D; Quinn DI; Moreno V; Doger B; Mayer IA; Boni V; Calvo E; Loi S; Lockhart AC; Erinjeri JP; Scaltriti M; Ulaner GA; Patel J; Tang J; Beer H; Selcuklu SD; Hanrahan AJ; Bouvier N; Melcer M; Murali R; Schram AM; Smyth LM; Jhaveri K; Li BT; Drilon A; Harding JJ; Iyer G; Taylor BS; Berger MF; Cutler RE; Xu F; Butturini A; Eli LD; Mann G; Farrell C; Lalani AS; Bryce RP; Arteaga CL; Meric-Bernstam F; Baselga J; Solit DB
Nature; 2018 Feb; 554(7691):189-194. PubMed ID: 29420467
[TBL] [Abstract][Full Text] [Related]
17. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.
Zheng Y; Shen G; Zhang C; Huo X; Xin Y; Fang Q; Guan Y; Zhao F; Ren D; Liu Z; Wang M; Zhao J
Clin Exp Med; 2023 Nov; 23(7):3205-3216. PubMed ID: 37120775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
